LBA76 Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
Year: 2024
Type: conference-abstract
Source: Annals of Oncology
Institutions: Peking University Cancer Hospital, Sichuan University, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Province Hospital, Chongqing University, Chongqing Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Hunan Cancer Hospital, Second Hospital of Tianjin Medical University, Liaoning Cancer Hospital & Institute, Chinese People's Liberation Army, People's Liberation Army Air Force, Air Force Medical University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, Nanjing Drum Tower Hospital, Nanjing University, Sun Yat-sen University Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, American Society of Clinical Oncology, Cleveland Clinic, Dana-Farber Cancer Institute, Exelixis, Goethe-Institut, Invitae, Eisai, European Society for Medical Oncology, Universitätsklinikum Jena, Institut Gustave-Roussy, Fundació Institut de Recerca Hospital Universitari Vall d’Hebron, Centre Léon Bérard, National Cancer Institute
OpenAlex ID: W4402565647